RESEARCH USE ONLY. Reference data for laboratory research. Not medical advice; not for human consumption.
Peptijournal
Calc

Compare compounds

Pick up to 3 compounds to see protocols, mechanisms, study endpoints and safety findings side by side.

PopularRetatrutide vs TirzepatideSemaglutide vs TirzepatideSemaglutide vs RetatrutideBPC-157 vs TB-500BPC-157 vs GHK-CuSermorelin vs Tesamorelin
Tesofensine
Same goal
Include when printing

Only affects the printed page / PDF. The research-use-only notice always prints.

Protocol01
Tesofensine

Metabolic / Weight

Vials · 10 mg

01Protocol

Vials
10 mg
Dosing data
Lab reference — not listed

02Quick calculator

Draw (100u)

—

Concentration

—

mg/mL

03Mechanism of action

Tesofensine is a small-molecule (not peptide) triple monoamine reuptake inhibitor (dopamine, noradrenaline and serotonin), originally studied for Parkinson's and Alzheimer's disease.

04Study endpoints

  • Phase 2 obesity trial (24 weeks): mean weight loss of 4.5%–10.6% across arms vs 2.0% with diet and placebo.
  • A mechanistic RCT found strong appetite-suppressing effects, a 4.6% higher night-time energy expenditure and greater 24-hour fat oxidation vs placebo.

05Safety & regulatory findings

  • Not approved by the FDA or EMA for any indication; research-grade material is not a medicine.
  • Monoamine reuptake inhibition is associated with heart-rate and blood-pressure increases, which were monitored in trials.

06Citations

2 references · view